Evidence map›Paper›PMID 33973200›Full record

ArticleAdvances in experimental medicine and biology2021

Prevention of COVID-19: Preventive Strategies for General Population, Healthcare Setting, and Various Professions.

Shirin Moossavi, Kelsey Fehr, Hassan Maleki, Simin Seyedpour, Mahdis Keshavarz-Fathi, Farhad Tabasi, Mehrdad Heravi, Rayka Sharifian, Golnaz Shafiei, Negin Badihian and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 4 countries.

Shirin MoossaviDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Canada.
Kelsey FehrChildren's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.
Hassan MalekiDepartment of Medical Nanotechnology and Nano Drug Delivery Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Simin SeyedpourSchool of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mahdis Keshavarz-FathiSchool of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Farhad TabasiSchool of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Mehrdad HeraviSchool of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Rayka SharifianMen's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Golnaz ShafieiGametogenesis Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Negin BadihianChild Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
Roya KelishadiChild Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
Shahrzad NematollahiUrology Research Taskforce (URT), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Majid AlmasiGametogenesis Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Saskia PopescuHonorHealth, Phoenix, AZ, USA.
Mahsa Keshavarz-FathiSchool of Medicine, Tehran University of Medical Sciences, Tehran, Iran. mahsa.keshavarz20@gmail.com.ORCID https://orcid.org/0000-0002-3836-1827
Nima RezaeiResearch Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Universal Scientific Education and Research Network · IREducation and Research Network · INIsfahan University of Medical Sciences · IRKashan University of Medical Sciences · IRChildren's Medical Center · IRKermanshah University of Medical Sciences · IRTarbiat Modares University · IRUniversity of Arizona · USUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The disease 2019 (COVID-19) made a public health emergency in early 2020. Despite attempts for the development of therapeutic modalities, there is no effective treatment yet. Therefore, preventive measures in various settings could help reduce the burden of disease. In this chapter, the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19, non-pharmaceutical approaches at individual and population level, chemoprevention, immunoprevention, preventive measures in different healthcare settings and other professions, special considerations in high-risk groups, and the role of organizations to hamper the psychosocial effects will be discussed.

Indexed as

Cancer VaccinesCOVID-19Delivery of Health CareHumansImmunotherapySARS-CoV-2Cancer VaccinesCOVID-19HealthcareNosocomial infectionPersonal protective equipmentPreventive measuresPsychological effectsVaccine

Identifiers

PMID33973200
OpenAlexW3162794241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.